T-cell therapy to neurodegenerative diseases
AssigneeBen-Gurion University of the Negev Research and Development Authority
InventorAlon Monsonego
Life of this patent
Estimating the term…
Abstract
Provided is a method of treating a pathology associated with neural damage, the method comprising administering non-antigen specific polyclonal activated T cells and/or genetically modified T cells into the brain in a manner which prevents meningoencephalitis in the subject, thereby treating the pathology associated with neural damage. Also provided are devices for intrabrain and intrathecal administration of T cells, which comprise the brain-specific or non-antigen specific polyclonal activated T cells and/or genetically modified T cells and a catheter for intrabrain administration in a manner which prevents meningoencephalitis in a subject.
Claims35
A method of treating a pathology associated with neural damage, the method comprising administering non-antigen specific polyclonal activated T cell into the brain in a manner which prevents meningoencephalitis in the subject, thereby treating the pathology associated with neural damage.
A method of administering a protein-of-interest into a brain of a subject, the method comprising administering a genetically modified T cell capable of expressing the protein-of-interest into the brain in a manner which prevents meningoencephalitis in the subject, thereby administering the protein-of-interest into the brain of the subject.
8-9. (canceled)
(canceled)
A method of treating a pathology associated with neural damage, the method comprising administering by intracerebroventricular (ICV) or intrathecal administration a polyclonal activated T cell into the brain, thereby treating the pathology associated with neural damage.
(canceled)
(canceled)
Dependencies are inferred from the claim text.